Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
暂无分享,去创建一个
K. Blennow | B. Winblad | J. Orgogozo | L. Minthon | M. Staufenbiel | N. Andreasen | G. Imbert | A. Graf | T. Dumortier | R. P. Maguire | A. Floesser | Joens Lundmark
[1] Janet B W Williams. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[2] M. Staufenbiel,et al. The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects , 2011, The Journal of Neuroscience.
[3] D. Selkoe,et al. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.
[4] D. Morgan. Immunotherapy for Alzheimer’s disease , 2011, Journal of internal medicine.
[5] T. Zako,et al. Amyloid oligomers: formation and toxicity of Aβ oligomers , 2010, The FEBS journal.
[6] Linus Jönsson,et al. The worldwide societal costs of dementia: Estimates for 2009 , 2010, Alzheimer's & Dementia.
[7] E. Masliah,et al. Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.
[8] N. Relkin,et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease , 2009, Neurobiology of Aging.
[9] M. Sapra,et al. Anti-amyloid treatments in Alzheimer's disease. , 2009, Recent patents on CNS drug discovery.
[10] Nick C Fox,et al. Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders , 2009, Current Alzheimer research.
[11] T. Wisniewski,et al. Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.
[12] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[13] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[14] D. Holtzman,et al. Active and passive immunotherapy for neurodegenerative disorders. , 2008, Annual review of neuroscience.
[15] Henrik Zetterberg,et al. Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.
[16] D. Peabody,et al. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. , 2006, Vaccine.
[17] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[18] I. Ferrer,et al. Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease , 2004, Brain pathology.
[19] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[20] C. Cotman,et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. , 2003, International immunology.
[21] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[22] K. Blennow,et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.
[23] K. Blennow,et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[24] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[25] K. Blennow,et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.
[26] B. Sommer,et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[27] K. Blennow,et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.
[28] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[29] J. Vickers,et al. Vaccination Strategies for Alzheimer’s Disease , 2007, Drugs & aging.
[30] K. Blennow,et al. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.
[31] R. Hu. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .